Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synthon, a pharma company into research, development, production, licensing and marketing of alternatives to innovative medicines, has got clearance for Tamsulosin extended release tablets, a generic version of Omnic Ocas 0.4mg extended release tablets, in all relevant European countries.
Subscribe to our email newsletter
Synthon has also completed registration procedures for Tamsulosin, reported PharmaLive.com.
Tamsulosin, an a1a-selective alpha blocker, contains the active ingredient Tamsulosin hydrochloride.
Developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma), Tamsulosin is indicated for the symptomatic treatment of men who are having difficulty urinating (benign prostatic hyperplasia).
It is marketed by various companies under licence, including Boehringer-Ingelheim and CSL.
Tamsulosin hydrochloride extended-release capsules are marketed under the trade names Flomax, Flomaxtra and Urimax, though generic non-modified release capsules are still approved and marketed in many countries, such as Canada.